Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Pfizer Stock Is Sliding Today

TheMotleyFool

0 0

Shares of Pfizer (NYSE: PFE) were sliding 3.1% lower as of 12:54 p.m. ET on Monday. The decline came after the big drugmaker announced that it is discontinuing the clinical development of vupanorsen. Pfizer licensed the experimental drug from Ionis Pharmaceuticals (NASDAQ: IONS) in November 2019. The company had been evaluating vupanorsen as a potential treatment for reducing cardiovascular risk and for severe hypertriglyceridemia.

This was a significant setback for Pfizer. The company had previously hoped that vupanorsen could generate peak sales of more than $3 billion. The experimental drug was one of several pipeline candidates that Pfizer expected would help it add at least $15 billion in annual revenue.

Image source: Getty Images.

Source Fool.com

Like: 0

PFE

Share